Skip to main content

Plus Therapeutics, Inc. (PSTV)

NASDAQ: PSTV · IEX Real-Time Price · USD
1.50 -0.03 (-1.96%)
Nov 26, 2021 1:00 PM EST - Market closed
Market Cap23.04M
Revenue (ttm)n/a
Net Income (ttm)-12.83M
Shares Out15.36M
EPS (ttm)-1.34
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,351,779
Open1.68
Previous Close1.53
Day's Range1.47 - 1.52
52-Week Range1.53 - 5.42
Beta0.35
AnalystsBuy
Price Target6.88 (+358.7%)
Earnings Daten/a

About PSTV

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium NanoLiposomes, a patented radiotherapy for patients with recurrent glioblastoma, which is in the Phase 1 dose-finding clinical trial. The company is also developing DocePLUS, a patented chemotherapy for patients with solid tumors that is in Phase 1 clinical trial; and DoxoPLUS, a generic chemotherapy for patients with ovarian...

IndustryBiotechnology
Founded1996
CEOMarc Hedrick
Employees12
Stock ExchangeNASDAQ
Ticker SymbolPSTV
Full Company Profile

Financial Performance

In 2020, PSTV's revenue was $303,000, a decrease of -95.67% compared to the previous year's $7.00 million. Losses were -$8.24 million, -24.30% less than in 2019.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for PSTV stock is "Buy." The 12-month stock price forecast is 6.88, which is an increase of 358.67% from the latest price.

Price Target
$6.88
(358.67% upside)
Analyst Consensus: Buy

News

Plus Therapeutics' Targeted Radiotherapy Shows Encouraging Overall Survival In Brain Tumour Trial

Plus Therapeutics Inc (NASDAQ: PSTV) released interim data from Phase 1 ReSPECT-GBM trial in patients with recurrent glioblastoma (GBM) of Rhenium-186 NanoLiposome (186RNL). According to the interim dat...

1 week ago - Benzinga

Plus Therapeutics Announces New Employment Inducement Grants

AUSTIN, Texas, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rar...

2 weeks ago - GlobeNewsWire

Plus Therapeutics Receives FDA Fast Track Designation for 186RNL Targeted Radiotherapeutic for Leptomeningeal Metastases

AUSTIN, Texas, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rar...

2 weeks ago - GlobeNewsWire

Plus Therapeutics Announces Presentation of ReSPECT-GBM Trial Dosimetery Data at the American Society for Radiation O...

Data demonstrated Rhenium-186 NanoLiposome ( 186 RNL) provides sustained, localized radiation treatment for over eight days to the tumor with minimal whole brain and body radiation exposure

4 weeks ago - GlobeNewsWire

Plus Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights

Management to host conference call today at 5:00 p.m. ET Management to host conference call today at 5:00 p.m. ET

1 month ago - GlobeNewsWire

Plus Therapeutics Announces FDA Clearance of Investigational New Drug Application for 186RNL for the Treatment of Lep...

Patient accrual for the Phase 1 dose escalation clinical trial of 186 RNL (ReSPECT-LM) is expected in the fourth quarter of 2021

1 month ago - GlobeNewsWire

Plus Therapeutics to Announce Third Quarter 2021 Financial Results and Host Conference Call on October 21, 2021

AUSTIN, Texas, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rar...

1 month ago - GlobeNewsWire

Plus Therapeutics to Present ReSPECT™-GBM Clinical Trial Data at the 2021 SNO Annual Meeting

AUSTIN, Texas, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics f...

1 month ago - GlobeNewsWire

Plus Therapeutics to Present Rhenium-186 NanoLiposome Data at the American Society for Radiation Oncology (ASTRO) 202...

AUSTIN, Texas, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for ra...

2 months ago - GlobeNewsWire

Plus Therapeutics Announces the Appointment of Industry Veteran, Norman LaFrance, M.D., as the Company's Chief Medica...

AUSTIN, Texas, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for ra...

2 months ago - GlobeNewsWire

Plus Therapeutics to Present at the H.C. Wainwright Global Investment Conference

AUSTIN, Texas, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for ra...

2 months ago - GlobeNewsWire

Why Is Plus Therapeutics Stock Moving Higher On Thursday?

Plus Therapeutics Inc (NASDAQ: PSTV) has entered into an agreement with RadioMedix Inc to produce the company's radiopharmaceuticals commercially. "This strategic partnership substantially supports our ...

2 months ago - Benzinga

Plus Therapeutics Announces Presentation of Data from the ReSPECT™-GBM Trial and Plans for Treating Pediatric Brain C...

Data shows that the administration of Rhenium-186 NanoLiposome ( 186 RNL) via convection enhanced delivery for recurrent glioblastoma is well tolerated at significantly higher doses of radiotherapy than...

3 months ago - GlobeNewsWire

Plus Therapeutics Presents Data from Preclinical Study of Rhenium-186 Nanoliposome in Leptomeningeal Metastases and P...

Positive data to support FDA IND application for the clinical evaluation of Rhenium-186 Nanoliposome ( 186 RNL) targeted radiotherapy for patients with leptomeningeal metastases (LM)

3 months ago - GlobeNewsWire

Plus Therapeutics to Present Data from ReSPECT™-GBM Trial at the American Association of Neurological Surgeons 2021 A...

AUSTIN, Texas, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted therapies for rare and di...

3 months ago - GlobeNewsWire

Plus Therapeutics to Present Data from Two Studies Supporting the Treatment of Leptomeningeal Metastases with Rhenium...

AUSTIN, Texas, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted therapies for rare and di...

3 months ago - GlobeNewsWire

Plus Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference

AUSTIN, Texas, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rar...

3 months ago - GlobeNewsWire

Plus Strengthens Commercial RNL Supply Chain with Ten Year Exclusivity Agreement

Global agreement covers 186 RNL manufacturing intermediate

4 months ago - GlobeNewsWire

Plus Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights

Management to host conference call today at 5:00 pm ET Management to host conference call today at 5:00 pm ET

4 months ago - GlobeNewsWire

Plus Therapeutics Shares Jump As First Patient Treated In Latest Cohort Of Brain Tumor Trial

Plus Therapeutics Inc (NASDAQ: PSTV) has announced that the first patient in the eighth cohort of Phase 1 dose-escalation ReSPECT-GBM trial for recurrent glioblastoma (rGBM) has been treated.  The prese...

4 months ago - Benzinga

Plus Therapeutics to Announce Second Quarter 2021 Financial Results and Host Conference Call on July 22, 2021

AUSTIN, Texas, July 15, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rar...

4 months ago - GlobeNewsWire

Plus Therapeutics Announces DSMB Approval to Proceed into Eighth Cohort in ReSPECT™ Glioblastoma Trial

AUSTIN, Texas, June 16, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficu...

5 months ago - GlobeNewsWire

Plus Therapeutics Presents at the Sixth Biennial Pediatric Neuro-Oncology Research Conference

AUSTIN, Texas, June 10, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company, today announced it will present a poster at the 6 th Bie...

5 months ago - GlobeNewsWire

Plus Therapeutics to Participate in BIO Digital Conference

AUSTIN, Texas, June 09, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company, today announced that Marc H. Hedrick M.D., President and...

5 months ago - GlobeNewsWire

Plus Therapeutics Announces Key RNL™ Development and cGMP Drug Manufacturing Collaboration Agreements

– Agreements are a major step for ongoing clinical trials and future commercial drug supply – Agreements are a major step for ongoing clinical trials and future commercial drug supply

6 months ago - GlobeNewsWire